{"id":"https://openalex.org/W2001328643","doi":"https://doi.org/10.1056/nejmoa1501031","title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","display_name":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","alternate_titles":[],"publication_year":2015,"publication_date":"2015-03-15","ids":{"openalex":"https://openalex.org/W2001328643","doi":"https://doi.org/10.1056/nejmoa1501031","mag":"2001328643","pmid":"https://pubmed.ncbi.nlm.nih.gov/25773378"},"language":"en","primary_location":{"id":"doi:10.1056/nejmoa1501031","doi":"https://doi.org/10.1056/nejmoa1501031","is_oa":true,"landing_page_url":"https://doi.org/10.1056/nejmoa1501031","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031?articleTools=true","source":{"id":"https://openalex.org/S62468778","display_name":"New England Journal of Medicine","issn_l":"0028-4793","issn":["0028-4793","0096-6762","1533-4406","2331-4710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320239","host_organization_name":"Massachusetts Medical Society","host_organization_lineage":["https://openalex.org/P4310320239"],"host_organization_lineage_names":["Massachusetts Medical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"New England Journal of Medicine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2001328643"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031?articleTools=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089418361","display_name":"Jennifer G. Robinson","orcid":"https://orcid.org/0000-0002-4432-4352","observed_orcids":["https://orcid.org/0000-0002-4432-4352"]},"institutions":[{"id":"https://openalex.org/I126307644","display_name":"University of Iowa","ror":"https://ror.org/036jqmy94","country_code":"US","type":"education","lineage":["https://openalex.org/I126307644"]},{"id":"https://openalex.org/I1281400175","display_name":"Oslo University Hospital","ror":"https://ror.org/00j9c2840","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I1281400175"]},{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I3019204325","display_name":"Centre Hospitalier Universitaire de Nantes","ror":"https://ror.org/05c1qsg97","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019204325"]}],"countries":["FR","NL","NO","US"],"is_corresponding":false,"raw_author_name":"Jennifer G. Robinson","raw_affiliation_strings":["From the University of Iowa, Iowa City (J.G.R.); Point M\u00e9dical, Dijon (M.F.), Centre Hospitalier Universitaire de Nantes-H\u00f4pital Nord Laennec, Saint-Herblain (M.K.), University Hospital of Lille, Lille (G. Luc), and Sanofi, Chilly-Mazarin (C.L.) - all in France; Clinique des Maladies Lipidiques de Qu\u00e9bec, Quebec, QC, Canada (J.B.); Universit\u00e0 di Palermo-Policlinico P. Giaccone, Palermo, Italy (M.A.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.S., J.J.P.K.); Lipid Clinic, Oslo University Hospital, Oslo (G. Langslet); University of the Witwatersrand, Johannesburg (F.J.R.); Cardiovascular Center of Sarasota, Sarasota (M.E.S.), and Jacksonville Center for Clinical Research, Jacksonville (M.J.K.) - both in Florida; Westside Medical Associates of Los Angeles, Beverly Hills, CA (N.E.L.); Regeneron Pharmaceuticals, Tarrytown, NY (R.P.); and Sanofi, Bridgewater, NJ (U.C.)","University of Iowa, Iowa City"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the University of Iowa, Iowa City (J.G.R.); Point M\u00e9dical, Dijon (M.F.), Centre Hospitalier Universitaire de Nantes-H\u00f4pital Nord Laennec, Saint-Herblain (M.K.), University Hospital of Lille, Lille (G. Luc), and Sanofi, Chilly-Mazarin (C.L.) - all in France; Clinique des Maladies Lipidiques de Qu\u00e9bec, Quebec, QC, Canada (J.B.); Universit\u00e0 di Palermo-Policlinico P. Giaccone, Palermo, Italy (M.A.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.S., J.J.P.K.); Lipid Clinic, Oslo University Hospital, Oslo (G. Langslet); University of the Witwatersrand, Johannesburg (F.J.R.); Cardiovascular Center of Sarasota, Sarasota (M.E.S.), and Jacksonville Center for Clinical Research, Jacksonville (M.J.K.) - both in Florida; Westside Medical Associates of Los Angeles, Beverly Hills, CA (N.E.L.); Regeneron Pharmaceuticals, Tarrytown, NY (R.P.); and Sanofi, Bridgewater, NJ (U.C.)","institution_ids":["https://openalex.org/I126307644","https://openalex.org/I1281400175","https://openalex.org/I2279609970","https://openalex.org/I2802928900","https://openalex.org/I3019204325"]},{"raw_affiliation_string":"University of Iowa, Iowa City","institution_ids":["https://openalex.org/I126307644"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037200495","display_name":"Michel Farnier","orcid":"https://orcid.org/0000-0002-0349-7978","observed_orcids":["https://orcid.org/0000-0002-0349-7978"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michel Farnier","raw_affiliation_strings":["Point M\u00e9dical, Dijon"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Point M\u00e9dical, Dijon","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043484813","display_name":"Michel Krempf","orcid":"https://orcid.org/0000-0002-4353-9511","observed_orcids":["https://orcid.org/0000-0002-4353-9511"]},"institutions":[{"id":"https://openalex.org/I3019204325","display_name":"Centre Hospitalier Universitaire de Nantes","ror":"https://ror.org/05c1qsg97","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019204325"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Michel Krempf","raw_affiliation_strings":["Centre Hospitalier Universitaire de Nantes\u2013H\u00f4pital Nord Laennec, Saint-Herblain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre Hospitalier Universitaire de Nantes\u2013H\u00f4pital Nord Laennec, Saint-Herblain","institution_ids":["https://openalex.org/I3019204325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061855686","display_name":"Jean Bergeron","orcid":"https://orcid.org/0000-0003-4007-8024","observed_orcids":["https://orcid.org/0000-0003-4007-8024","https://orcid.org/0000-0001-6279-5054"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jean Bergeron","raw_affiliation_strings":["Clinique des Maladies Lipidiques de Qu\u00e9bec, Quebec, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinique des Maladies Lipidiques de Qu\u00e9bec, Quebec, QC, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113631737","display_name":"G\u00e9rald Luc","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"G\u00e9rald Luc","raw_affiliation_strings":["University Hospital of Lille, Lille"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital of Lille, Lille","institution_ids":["https://openalex.org/I2279609970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073159448","display_name":"Maurizio Rocco Averna","orcid":"https://orcid.org/0000-0003-3558-9209","observed_orcids":["https://orcid.org/0000-0003-3558-9209"]},"institutions":[{"id":"https://openalex.org/I4210147076","display_name":"Azienda Ospedaliera Universitaria Policlinico \"Paolo Giaccone\" di Palermo","ror":"https://ror.org/05p21z194","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210147076"]},{"id":"https://openalex.org/I900890020","display_name":"University of Palermo","ror":"https://ror.org/044k9ta02","country_code":"IT","type":"education","lineage":["https://openalex.org/I900890020"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Maurizio Averna","raw_affiliation_strings":["Universit\u00e0 di Palermo\u2013Policlinico P. Giaccone, Palermo, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e0 di Palermo\u2013Policlinico P. Giaccone, Palermo, Italy","institution_ids":["https://openalex.org/I4210147076","https://openalex.org/I900890020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081557648","display_name":"Erik S.G. Stroes","orcid":"https://orcid.org/0000-0001-9555-6260","observed_orcids":["https://orcid.org/0000-0001-9555-6260","https://orcid.org/0009-0000-7584-7677"]},"institutions":[{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Erik S. Stroes","raw_affiliation_strings":["Department of Vascular Medicine, Academic Medical Center, Amsterdam"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Vascular Medicine, Academic Medical Center, Amsterdam","institution_ids":["https://openalex.org/I2802928900"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009467334","display_name":"Gisle Langslet","orcid":"https://orcid.org/0000-0003-4034-2243","observed_orcids":["https://orcid.org/0000-0003-4034-2243"]},"institutions":[{"id":"https://openalex.org/I1281400175","display_name":"Oslo University Hospital","ror":"https://ror.org/00j9c2840","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I1281400175"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Gisle Langslet","raw_affiliation_strings":["Lipid Clinic, Oslo University Hospital, Oslo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lipid Clinic, Oslo University Hospital, Oslo","institution_ids":["https://openalex.org/I1281400175"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044425699","display_name":"Frederick Johan Raal","orcid":"https://orcid.org/0000-0002-9170-7938","observed_orcids":["https://orcid.org/0000-0002-9170-7938"]},"institutions":[{"id":"https://openalex.org/I192619145","display_name":"University of the Witwatersrand","ror":"https://ror.org/03rp50x72","country_code":"ZA","type":"education","lineage":["https://openalex.org/I192619145"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Frederick J. Raal","raw_affiliation_strings":["University of the Witwatersrand, Johannesburg"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of the Witwatersrand, Johannesburg","institution_ids":["https://openalex.org/I192619145"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091562154","display_name":"Mahfouz El Shahawy","orcid":"https://orcid.org/0000-0002-0456-6971","observed_orcids":["https://orcid.org/0000-0002-0456-6971"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mahfouz El Shahawy","raw_affiliation_strings":["Cardiovascular Center of Sarasota, Sarasota"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardiovascular Center of Sarasota, Sarasota","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032891959","display_name":"Michael J. Koren","orcid":"https://orcid.org/0000-0001-5023-7178","observed_orcids":["https://orcid.org/0000-0001-5023-7178"]},"institutions":[{"id":"https://openalex.org/I4210135343","display_name":"Jacksonville Center for Clinical Research","ror":"https://ror.org/03ftkmq63","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210135343"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Koren","raw_affiliation_strings":["Jacksonville Center for Clinical Research, Jacksonville"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jacksonville Center for Clinical Research, Jacksonville","institution_ids":["https://openalex.org/I4210135343"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043161884","display_name":"Norman E. Lepor","orcid":"https://orcid.org/0000-0002-4777-5714","observed_orcids":["https://orcid.org/0000-0002-4777-5714"]},"institutions":[{"id":"https://openalex.org/I4210150012","display_name":"Westside Medical Associates of Los Angeles","ror":"https://ror.org/04fj57991","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210150012"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norman E. Lepor","raw_affiliation_strings":["Westside Medical Associates of Los Angeles, Beverly Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Westside Medical Associates of Los Angeles, Beverly Hills, CA","institution_ids":["https://openalex.org/I4210150012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033229851","display_name":"Christelle Lorenzato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christelle Lorenzato","raw_affiliation_strings":["Sanofi, Chilly-Mazarin"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Chilly-Mazarin","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042842097","display_name":"Robert C. Pordy","orcid":"https://orcid.org/0000-0002-8001-6795","observed_orcids":["https://orcid.org/0000-0002-8001-6795"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Pordy","raw_affiliation_strings":["Regeneron Pharmaceuticals, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074320934","display_name":"Umesh Chaudhari","orcid":"https://orcid.org/0000-0002-7743-4371","observed_orcids":["https://orcid.org/0000-0002-7743-4371"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Umesh Chaudhari","raw_affiliation_strings":["Sanofi, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Bridgewater, NJ","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077848934","display_name":"John J.P. Kastelein","orcid":"https://orcid.org/0000-0003-2018-4532","observed_orcids":["https://orcid.org/0000-0003-2018-4532"]},"institutions":[{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"John J.P. Kastelein","raw_affiliation_strings":["Department of Vascular Medicine, Academic Medical Center, Amsterdam"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Vascular Medicine, Academic Medical Center, Amsterdam","institution_ids":["https://openalex.org/I2802928900"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":240.2636,"has_fulltext":true,"cited_by_count":2453,"citation_normalized_percentile":{"value":0.99988695,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"372","issue":"16","first_page":"1489","last_page":"1499"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alirocumab","display_name":"alirocumab","score":0.9739999771118164},{"id":"https://openalex.org/keywords/pcsk9-inhibition","display_name":"PCSK9 inhibition","score":0.9269999861717224},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.9200000166893005},{"id":"https://openalex.org/keywords/statin-therapy","display_name":"statin therapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9290000200271606},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.6790000200271606},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.6949999928474426},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.734000027179718},{"id":"https://openalex.org/keywords/high-risk-patients","display_name":"high-risk patients","score":0.5170000195503235},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.9194159507751465},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4375157952308655},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2497226893901825},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.14924389123916626},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.12025323510169983},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D057194","descriptor_name":"Intention to Treat Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":10,"locations":[{"id":"doi:10.1056/nejmoa1501031","doi":"https://doi.org/10.1056/nejmoa1501031","is_oa":true,"landing_page_url":"https://doi.org/10.1056/nejmoa1501031","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031?articleTools=true","source":{"id":"https://openalex.org/S62468778","display_name":"New England Journal of Medicine","issn_l":"0028-4793","issn":["0028-4793","0096-6762","1533-4406","2331-4710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320239","host_organization_name":"Massachusetts Medical Society","host_organization_lineage":["https://openalex.org/P4310320239"],"host_organization_lineage_names":["Massachusetts Medical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"New England Journal of Medicine","raw_type":"journal-article"},{"id":"pmid:25773378","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25773378","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The New England journal of medicine","raw_type":"Comparative Study"},{"id":"pmid:25773607","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25773607","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The New England journal of medicine","raw_type":"Comparative Study"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire/9e6c3f82-0a56-4a32-8911-38458bd2e791","doi":null,"is_oa":true,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/9e6c3f82-0a56-4a32-8911-38458bd2e791","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Robinson, J G, Farnier, M, Krempf, M, Bergeron, J, Luc, G, Averna, M, Stroes, E S, Langslet, G, Raal, F J, El Shahawy, M, Koren, M J, Lepor, N E, Lorenzato, C, Pordy, R, Chaudhari, U, Kastelein, J J P & AUTHOR GROUP 2015, 'Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events', New England journal of medicine, vol. 372, no. 16, pp. 1489-1499. https://doi.org/10.1056/NEJMoa1501031","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.atira.dk:publications/67230f3f-c62a-483a-be44-43a1da6bc14f","doi":null,"is_oa":false,"landing_page_url":"https://vbn.aau.dk/da/publications/67230f3f-c62a-483a-be44-43a1da6bc14f","pdf_url":null,"source":{"id":"https://openalex.org/S4306401731","display_name":"VBN Forskningsportal (Aalborg Universitet)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I891191580","host_organization_name":"Aalborg University","host_organization_lineage":["https://openalex.org/I891191580"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Robinson, J G, Farnier, M, Krempf, M, Bergeron, J, Luc, G, Averna, M, Stroes, E S, Langslet, G, Raal, F J, El Shahawy, M, Koren, M J, Lepor, N E, Lorenzato, C, Pordy, R, Chaudhari, U, Kastelein, J J P, ODYSSEY LONG TERM Investigators & Torp-Pedersen, C 2015, 'Efficacy and safety of alirocumab in reducing lipids and cardiovascular events', The New England Journal of Medicine, vol. 372, no. 16, pp. 1489-1499. https://doi.org/10.1056/NEJMoa1501031","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/a9ddbe88-f906-49fd-b1da-2f79a57492b4","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/efficacy-and-safety-of-alirocumab-in-reducing-lipids-and-cardiovascular-events(a9ddbe88-f906-49fd-b1da-2f79a57492b4).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"New England journal of medicine, 372(16), 1489 - 1499. Massachussetts Medical Society","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:HAL:hal-02641589v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.inrae.fr/hal-02641589","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"New England Journal of Medicine, 2015, 372 (16), pp.1489-1499. &#x27E8;10.1056/NEJMoa1501031&#x27E9;","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:alma.44SUR_INST:11208990380002346","doi":null,"is_oa":false,"landing_page_url":"https://openresearch.surrey.ac.uk/esploro/outputs/journalArticle/Efficacy-and-Safety-of-Alirocumab-in/99913565102346","pdf_url":null,"source":{"id":"https://openalex.org/S7407059866","display_name":"University of Surrey Open Research repository","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"text"},{"id":"pmh:oai:iris.unipa.it:10447/127416","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10447/127416","pdf_url":null,"source":{"id":"https://openalex.org/S4306401065","display_name":"Nova Science Publishers (Nova Science Publishers, Inc.)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:iris.uniroma1.it:11573/782994","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/11573/782994","pdf_url":null,"source":{"id":"https://openalex.org/S4377196107","display_name":"IRIS Research product catalog (Sapienza University of Rome)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1056/nejmoa1501031","doi":"https://doi.org/10.1056/nejmoa1501031","is_oa":true,"landing_page_url":"https://doi.org/10.1056/nejmoa1501031","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031?articleTools=true","source":{"id":"https://openalex.org/S62468778","display_name":"New England Journal of Medicine","issn_l":"0028-4793","issn":["0028-4793","0096-6762","1533-4406","2331-4710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320239","host_organization_name":"Massachusetts Medical Society","host_organization_lineage":["https://openalex.org/P4310320239"],"host_organization_lineage_names":["Massachusetts Medical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"New England Journal of Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2001328643.pdf","grobid_xml":"https://content.openalex.org/works/W2001328643.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W121888607","https://openalex.org/W161816689","https://openalex.org/W162053157","https://openalex.org/W1856460279","https://openalex.org/W1967021869","https://openalex.org/W1968507301","https://openalex.org/W1972661406","https://openalex.org/W2014561045","https://openalex.org/W2016779584","https://openalex.org/W2019071303","https://openalex.org/W2024930123","https://openalex.org/W2047955620","https://openalex.org/W2048760408","https://openalex.org/W2054572833","https://openalex.org/W2059870401","https://openalex.org/W2067539811","https://openalex.org/W2090244882","https://openalex.org/W2096075279","https://openalex.org/W2103487568","https://openalex.org/W2103647780","https://openalex.org/W2106285889","https://openalex.org/W2108956796","https://openalex.org/W2116404316","https://openalex.org/W2118825330","https://openalex.org/W2119475560","https://openalex.org/W2121581403","https://openalex.org/W2128030263","https://openalex.org/W2148577580","https://openalex.org/W2155259933","https://openalex.org/W2158870651","https://openalex.org/W2163238468","https://openalex.org/W2164089346","https://openalex.org/W2165605025","https://openalex.org/W2247997571","https://openalex.org/W2329449966"],"related_works":["https://openalex.org/W3009029680","https://openalex.org/W2053355529","https://openalex.org/W1985747185","https://openalex.org/W2592844101","https://openalex.org/W2889598530","https://openalex.org/W2557775681","https://openalex.org/W1963068957","https://openalex.org/W2595407739","https://openalex.org/W2902577254","https://openalex.org/W2786107694"],"abstract_inverted_index":{"BACKGROUND:":[0],"Alirocumab,":[1],"a":[2,44,103,114,178,217,269,291,299],"monoclonal":[3],"antibody":[4],"that":[5],"inhibits":[6],"proprotein":[7],"convertase":[8],"subtilisin-kexin":[9],"type":[10],"9":[11],"(PCSK9),":[12],"has":[13],"been":[14],"shown":[15],"to":[16,36,106,140,263,277],"reduce":[17],"low-density":[18],"lipoprotein":[19],"(LDL)":[20],"cholesterol":[21,59,136,165,288],"levels":[22,60],"in":[23,102,133,155,162,301],"patients":[24,49],"who":[25,56],"are":[26,34],"receiving":[27,74],"statin":[28,278],"therapy.":[29,97],"Larger":[30],"and":[31,39,72,152,210,312],"longer-term":[32],"studies":[33],"needed":[35],"establish":[37],"safety":[38],"efficacy.":[40],"METHODS:":[41],"We":[42],"conducted":[43],"randomized":[45],"trial":[46],"involving":[47],"2341":[48],"at":[50,78,280],"high":[51],"risk":[52],"for":[53,121],"cardiovascular":[54,226,305],"events":[55,206,212,227,306],"had":[57,192],"LDL":[58,135,164,287],"of":[61,180,195,223,271,298,304],"70":[62],"mg":[63],"per":[64,68],"deciliter":[65],"(1.8":[66],"mmol":[67],"liter)":[69],"or":[70,93,111,237,241],"more":[71],"were":[73,99],"treatment":[75,173],"with":[76,87,92,188,248,251,307],"statins":[77],"the":[79,130,147,150,156,172,189,221,281,302],"maximum":[80,282],"tolerated":[81,283],"dose":[82,85],"(the":[83],"highest":[84],"associated":[86],"an":[88],"acceptable":[89],"side-effect":[90],"profile),":[91],"without":[94],"other":[95],"lipid-lowering":[96],"Patients":[98],"randomly":[100],"assigned":[101],"2:1":[104],"ratio":[105],"receive":[107],"alirocumab":[108,151,184,249],"(150":[109],"mg)":[110],"placebo":[112,153,190,252],"as":[113,186],"1-ml":[115],"subcutaneous":[116],"injection":[117],"every":[118],"2":[119],"weeks":[120],"78":[122,181,272],"weeks.":[123,182],"The":[124,183],"primary":[125],"efficacy":[126],"end":[127],"point":[128],"was":[129,167,246,296],"percentage":[131,158,169],"change":[132,159],"calculated":[134,163],"level":[137,166],"from":[138,160,229],"baseline":[139,161],"week":[141,145],"24.":[142],"RESULTS:":[143],"At":[144],"24,":[146],"difference":[148],"between":[149],"groups":[154],"mean":[157],"-62":[168],"points":[170],"(P<0.001);":[171],"effect":[174],"remained":[175],"consistent":[176],"over":[177],"period":[179,270],"group,":[185,191],"compared":[187],"higher":[193],"rates":[194],"injection-site":[196],"reactions":[197],"(5.9%":[198],"vs.":[199,203,208,214,254],"4.2%),":[200],"myalgia":[201],"(5.4%":[202],"2.9%),":[204],"neurocognitive":[205],"(1.2%":[207],"0.5%),":[209],"ophthalmologic":[211],"(2.9%":[213],"1.9%).":[215],"In":[216,290],"post":[218,292],"hoc":[219,293],"analysis,":[220,294],"rate":[222,303],"major":[224],"adverse":[225],"(death":[228],"coronary":[230],"heart":[231],"disease,":[232],"nonfatal":[233,238],"myocardial":[234],"infarction,":[235],"fatal":[236],"ischemic":[239],"stroke,":[240],"unstable":[242],"angina":[243],"requiring":[244],"hospitalization)":[245],"lower":[247],"than":[250],"(1.7%":[253],"3.3%;":[255],"hazard":[256],"ratio,":[257],"0.52;":[258],"95%":[259],"confidence":[260],"interval,":[261],"0.31":[262],"0.90;":[264],"nominal":[265],"P=0.02).":[266],"CONCLUSIONS:":[267],"Over":[268],"weeks,":[273],"alirocumab,":[274],"when":[275],"added":[276],"therapy":[279],"dose,":[284],"significantly":[285],"reduced":[286],"levels.":[289],"there":[295],"evidence":[297],"reduction":[300],"alirocumab.":[308],"(Funded":[309],"by":[310],"Sanofi":[311],"Regeneron":[313],"Pharmaceuticals;":[314],"ODYSSEY":[315],"LONG":[316],"TERM":[317],"ClinicalTrials.gov":[318],"number,":[319],"NCT01507831.).":[320]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2001328643","counts_by_year":[{"year":2026,"cited_by_count":85},{"year":2025,"cited_by_count":122},{"year":2024,"cited_by_count":165},{"year":2023,"cited_by_count":151},{"year":2022,"cited_by_count":136},{"year":2021,"cited_by_count":168},{"year":2020,"cited_by_count":183},{"year":2019,"cited_by_count":243},{"year":2018,"cited_by_count":265},{"year":2017,"cited_by_count":358},{"year":2016,"cited_by_count":382},{"year":2015,"cited_by_count":185},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
